title: [Research on therapeutic effects of bufonis venenum on L7212 leukemia and its mechanism].
abstract: OBJECTIVE
  To study the therapeutic effects of Bufonis Venenum on L7212 leukemia and the potential mechanism.
  
  
  METHODS
  L7212 leukemia model mice were randomly divided into four groups: model group, low and high dose Bufonis Venenum groups and chemotherapy group. Normal mice were treated as control group. Mice were injected intraperitoneally for 10 days continually. The body weight, survival time, peripheral blood leukocyte, hepatic and splenic indexes, bone marrow leukocyte and T lymphocyte were observed and determined.
  
  
  RESULTS
  Body weight of L7212 leukemia model group mice were decreased significantly. Compared with other groups, high dose Bufonis Venenum group's weight loss was the least. Bufonis Venenum groups survived longer than L7212 model group. Compared with model group, high dose Bufonis Venenum group's liver index was higher (P < 0.05). After inoculation for 1 day, leukocyte count as well as percentage of leukemic cells within five groups had no significant difference (P > 0.05). Compared with the model group, after inoculation for 10 days, leukocyte count in Bufonis Venenum groups and the chemotherapy group were significantly reduced (P < 0.05). Percentage of leukemia cells in blood and bone marrow in high dose Bufonis Venenum group was significantly decreased (P < 0.05). Compared with model group, CD3+ and CD4+ in Bufonis Venenum groups and the chemotherapy group were increased, CD8+ was decreased, but had no significant difference (P > 0.05).
  
  
  CONCLUSIONS
  Bufonis Venenum has therapeutic effects on the L7212 leukemia by inducing apoptosis and improving immune system.
authors.forename: Yue
authors.initials: Y
authors.lastname: Xiao
authors.forename: Qian-Fu
authors.initials: QF
authors.lastname: Xue
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001835:Body Weight; D002018:Bufanolides / Q000008:administration & dosage / Q000494:pharmacology*; D002025:Bufonidae; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008419:Materia Medica / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D011897:Random Allocation; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D002018:Bufanolides; D008419:Materia Medica